Stereotactic body radiation therapy for pleural mesothelioma: which goal, which patients
We read with interest the article by Shin et al. [1], recently published in Radiotherapy& Oncology. We commend the authors for reporting the results of the largest cohort to date investigating Stereotactic Body Radiation Therapy (SBRT) in pleural mesothelioma (PM). We fully agree with their conclusions that an adequate local control in this setting without significant toxicity can be achieved with non-ablative total doses, keeping the dose per fraction relatively high. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Giovanni L. Ceresoli, Paolo Ghirardelli, Vittorio Vavassori Tags: Letter to the Editor Source Type: research
Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – a DAHANCA 19 study
Following primary radiotherapy (RT), the outcome for patients with head and neck squamous cell carcinoma (HNSCC) has improved over the last decades [1]. This may partly be explained by the increasing frequency of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) [2], and partly by intensified treatment regimens including technical and biological optimization. In Denmark, loco-regional control has improved with the addition of hypoxic sensitization (nimorazole) [3], reduced overall treatment time (6 fractions/week), and concomitant chemotherapy, adjusted for the influence of stage and HPV-stat...
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Morten Horsholt Kristensen, Mia Kristina S ørensen, Trine Tramm, Jan Alsner, Brita Singers Sørensen, Christian Maare, Jørgen Johansen, Hanne Primdahl, Åse Bratland, Claus Andrup Kristensen, Maria Andersen, Jacob Kinggaard Lilja-Fischer, Anne Ivalu Sa Tags: Original Article Source Type: research
Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: a cross-sectional study
Treatment outcomes for nasopharyngeal carcinoma (NPC) have improved significantly over the past few decades. With the advances in radiotherapy techniques and systemic chemotherapy,5-year survival rates as high as 70 – 85% are expected forpatients with loco-regionally advanced diseases.[1] Although the advent of modern intensity-modulated radiotherapy (IMRT) techniques has greatly improved tumor target conformity, radiation that traverses normal tissue continues to bring along late complications that greatly i mpair the quality of life of long-term survivors. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: James C.H. Chow, Jack Lee, Maria M.P. Lai, Sara Li, Adelina M.C. Lau, Beni S.Y. Ng, Gigi G.G. Leung, Sharon T.Y. Li, Jeffrey C.F. Lui, K.M. Cheung, K.H. Au, K.H. Wong, Alexander Y.L. Lau, Benny C.Y Zee Tags: Original Article Source Type: research
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42 / GERICO 12 study) : quality of life and comprehensive geriatric assessment
Recent progress in the management of locally advanced rectal cancers with intensification of neoadjuvant strategies has improved local control [1], relapse-free survival [2,3] and even overall survival [4]. The corollary of these progressive intensifications has been an increase in side effects, which may have important consequences, in particular in fragile populations like the elderly [5]. 2-year mortality in the most fragile elderly patients exceeds 40% [6], and it amounts to 16-25% in the group of patients who are beginning to lose their autonomy and/or present co-morbidities [6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Eric Fran çois, Nicolas Magné, Rabia Boulahssass, Philippe Ronchin, Virginie Huguenet, Blandine De Lavigerie, Elodie Nouhaud, atherine Cattenoz, Isabelle Martel-Lafay, Catherine Terret, Pascal Artru, Pierre Clavere, Achille Tchalla, Veronique Vendrely, Tags: Original Article Source Type: research
Optimal timing of re-planning for head and neck adaptive radiotherapy
Adaptive radiotherapy (ART) for head and neck cancer patients has been studied for over 25 years since proposed by Yan et al in 1997[1]. Current practice of ART is particularly aiming to spare organs at risk (OARs) as the leading purpose or most important benefit [2], but is not yet widely applied in routine clinical practice due to the challenges of identifying: 1) the most relevant candidate patients and 2) the optimal timing of re-planning [3,4]. Previous studies have shown up to 10.6% of head and neck cancer patients require re-planning [56]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Yong Gan, Johannes A. Langendijk, Edwin Oldehinkel, Zhixiong Lin, Stefan Both, Charlotte L. Brouwer Tags: Original Article Source Type: research
Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer
Non-small cell lung carcinoma (NSCLC) stage III accounts for 25-30% of all patients with NSCLC.[1] Patients with stage III NSCLC have frequently unresectable disease.[2] Concurrent chemoradiotherapy (cCRT) is the preferred non-surgical treatment for such patients, yet the best 5-year overall survival (OS) (32%) and progression free survival (PFS) (18%) reported in a phase III randomized controlled trial are disappointing.[3] The PACIFIC regimen is the paradigm establishing a survival benefit for adjuvant durvalumab, an anti —PD-L1 antibody after cCRT. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: I. Smesseim, O.M. Mets, J.M.A. Daniels, I. Bahce, S. Senan Tags: Original Article Source Type: research
Applying the Fragility Index to Randomized Controlled Trials Evaluating Total Neoadjuvant Therapy for Rectal Cancer: A Methodological Survey
Level I evidence, the highest quality evidence, comes from randomized controlled trials (RCTs).[1]The impact of level I evidence (i.e., RCTs) on clinical practice is largely determined by the presence of statistically significant findings, or lack thereof. This is most referenced in terms of the p-value. A cut-off value of 0.05 or less for p-values denotes a treatment effect that is unlikely to be due to chance alone.[2] However, the American Statistical Association (ASA) has criticized the use of the p-value alone due to the arbitrary cut-off value and the lack of consideration for the treatment effect size and the precis...
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Tyler McKechnie, Kelly Brennan, Cagla Eskicioglu, Ameer Farooq, Sunil Patel Tags: Review Article Source Type: research
Shared decision making with breast cancer patients – does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial
Patient engagement in decision making is indispensably on the international healthcare agenda [1 –7] with shared decision making (SDM) as a widely recognized patient engaging process especially advocated for preference-sensitive decisions [8–10]. Taking patient preferences into account is salient in transforming modern medicine into meaningful care [11,12], However, SDM has proven difficult to implement in daily clinic [13], which has encouraged its inclusion as a fundamental patient right in national health care standards and legislation [14–17]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 3, 2024 Category: Radiology Authors: Stine Rauff S øndergaard, Troels Bechmann, Else Maae, Anders W. Mølby Nielsen, Mette Holck Nielsen, Mette Møller, Signe Timm, Ebbe Laugaard Lorenzen, Leonard L. Berry, Robert Zachariae, Birgitte Vrou Offersen, Karina Dahl Steffensen Tags: Original Article Source Type: research
Shared decision making with breast cancer patients - does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial
Patient engagement in decision making is indispensably on the international healthcare agenda1 –7 with shared decision making (SDM) as a widely recognized patient engaging process especially advocated for preference-sensitive decisions.8–10 Taking patient preferences into account is salient in transforming modern medicine into meaningful care,11,12 However, SDM has proven difficult to imp lement in daily clinic,13 which has encouraged its inclusion as a fundamental patient right in national health care standards and legislation. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 3, 2024 Category: Radiology Authors: Stine Rauff S øndergaard, Troels Bechmann, Else Maae, Anders W Mølby Nielsen, Mette Holck Nielsen, Mette Møller, Signe Timm, Ebbe Laugaard Lorenzen, Leonard L. Berry, Robert Zachariae, Birgitte Vrou Offersen, Karina Dahl Steffensen Tags: Original Article Source Type: research
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial
Radiation therapy is a standard treatment for patients with locally advanced squamous cell carcinoma of the head and neck [1,2]. Among the existing radiotherapy techniques, intensity modulated radiotherapy (IMRT) is the recommended treatment [3]. Indeed, this technique makes it possible to reduce the doses of radiation administered to the parotid glands at the planning stage and thus to reduce xerostomia in these patients [4 –6]. The parotid glands are the major tissues responsible for salivary output, contributing up to 70% of the salivary flow [7]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Lionel Perrier, Fr édéric Balusson, Magali Morelle, Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, Antoine Berger, Xavier Liem, Sébastien Guihard, Sophie Chapet, Sébastien Thureau, Pierre Auberdiac, Pascal Pommier, Amandi Tags: Original Article Source Type: research
Common Sense (Radiation) Oncology: Redefining Targets in Radiotherapy
In 2023, the Common Sense Oncology (CSO) movement was launched with the goal of recalibrating cancer care to focus on outcomes that matter to patients. We extend the three CSO pillars – evidence generation, interpretation and communication – to radiation oncology and advocate for better evidence demonstrating the value of our modality. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Nina N. Sanford, Yolande Lievens, Ajay Aggarwal, Timothy Hanna, Laura Dawson, Jeffrey White, Bishal Gyawali, Christopher Booth, Fabio Ynoe de Moraes Tags: Short Communication Source Type: research
Definitive single fraction spine stereotactic radiosurgery for metastatic sarcoma: Simultaneous integrated boost is associated with high tumor control and low vertebral fracture risk
Sarcoma spinal metastases (SSM) are particularly difficult to manage given their poor response rates to chemotherapy and inherent radioresistance. We evaluated outcomes in a cohort of patients with SSM uniformly treated using single-fraction simultaneous-integrated-boost (SIB) spine stereotactic radiosurgery (SSRS). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Mihir D. Shanker, Adriana P. Cavazos, Jing Li, Thomas H. Beckham, Debra N. Yeboa, Chenyang Wang, Mary Frances McAleer, Tina M. Briere, Behrang Amini, Claudio E. Tatsui, Robert Y. North, Christopher A. Alvarez-Breckenridge, Phillip Cezayirli, Laurence D. R Tags: Original Article Source Type: research
Paediatric Radiation Therapy without Anaesthesia – Are the Children Moving?
Although generally safe [1], use of anaesthesia in paediatric radiation oncology can be costly [2] and cumbersome, and adds to the burden of cancer treatment in children and adolescents.[3,4] In many institutions, a substantial proportion of young children and some adolescents undergo general anaesthesia for radiation treatments.[2,5] At our institution, a multi-faceted approach has been used to reduce anaesthesia utilization as part of standard-of-care radiotherapy (RT): presence of a dedicated paediatric nurse for procedural preparation, comfort objects (e.g., stuffed animal), and most importantly, audiovisual distractio...
Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Tatiana Ritchie, Susan Awrey, Manjula Maganti, Rehab Chahin, Michael Velec, David C. Hodgson, Hitesh Dama, Sameera Ahmed, Jeff D. Winter, Normand Laperriere, Derek S. Tsang Tags: Original Article Source Type: research
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma
For 20 years, the standard therapy for inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC) was definitive concurrent chemotherapy and photon radiation therapy (RT). In 2018, based on the findings from the landmark PACIFIC trial demonstrating an overall survival (OS) benefit from adding adjuvant durvalumab to standard chemotherapy and photon RT, the US Food and Drug Administration approved the adjuvant ICI durvalumab as a new standard of care in such cases.[1,2] Nevertheless, RT-related cardiac and pulmonary toxicity remains a significant source of morbidity and mortality in LA-NSCLC survivors,[3,4] and rad...
Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Kelsey L. Corrigan, Ting Xu, Yuki Sasaki, Ruitao Lin, Aileen B. Chen, James W. Welsh, Steven H. Lin, Joe Y. Chang, Matthew S. Ning, Saumil Gandhi, Michael S. O'Reilly, Carl M. Gay, Mehmet Altan, Charles Lu, Tina Cascone, Efstratios Koutroumpakis, Ajay She Tags: Original Article Source Type: research
GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey
Uveal melanoma is the most common primary intraocular malignancy in adults. In contrast to enucleation, radiation therapy offers eye preserving treatment options like brachytherapy (BT, also called interventional radiotherapy), generally using Ruthenium-106 or Iodine-125, and external beam radiation therapy (EBRT) using photons or protons. Other options are photo-dynamic therapy (PDT) or transpupillary thermotherapy (TTT). 106Ru ocular plaque BT is a niche treatment performed in only about 100 clinics worldwide [2 –5]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 1, 2024 Category: Radiology Authors: Marisol De Brabandere, Elisa Placidi, Frank-Andr é Siebert, Åsa Carlsson Tedgren, Andrea Slocker Escarpa, Luca Tagliaferri, Michael Andrássy, Carmen Schulz, Lotte S. Fog Tags: Original Article Source Type: research
